市场调查报告书
商品编码
1368679
适体市场规模 - 按类型(DNA、RNA 适体)、应用(研究与开发、诊断)、技术 (SELEX)、最终用途和全球预测 - 2023 年 - 2032 年Aptamers Market Size - By Type (DNA, RNA-Based Aptamers), Application (Research & Development, Diagnostics), Technology (SELEX), End-use & Global Forecast - 2023 - 2032 |
由于慢性病盛行率上升以及对标靶治疗和个人化医疗解决方案的需求激增,预计 2023 年至 2032 年适体市场规模将以超过 20% 的复合年增长率成长。适体因其对各种疾病标靶的高特异性和亲和力,作为传统治疗方式的可行替代方案而受到关注。由于其具有精确有效的药物输送潜力以及最小的脱靶效应和降低的免疫原性,适配体正在满足对个人化医疗解决方案不断增长的需求。
此外,产业参与者正在投资研发活动,以推动适配体技术的进步。例如,2023 年 10 月,Zentek Ltd. 与麦克马斯特大学合作成立了一家全资子公司,该子公司将拥有所有基于适配体的技术的独家国际许可权。
整个适配体市场分为类型、应用、技术、最终用途和区域。
根据类型,基于 RNA 的适配体产业预计将在 2023 年至 2032 年期间获得显着成长。凭藉其与多种标靶分子结合的独特能力,基于RNA的适配体在治疗、诊断和研究应用领域引起了极大的关注。此外,RNA适体选择技术的不断进步,包括改进的SELEX方法和正在进行的研发活动,以探索基于RND的适体的潜在应用,将推动该细分市场的成长。例如,2023 年 9 月,FDA 授权 Iveric Bio/Astellas 的 avacincapad pegol 治疗继发性地图样萎缩,以治疗老年黄斑部病变。
在应用方面,预计到2032 年,诊断领域的适配体市场规模将实现强劲增长。由于其快速、灵敏的检测能力以及更高的多重检测潜力和经济高效的生产,适配体已成为诊断领域的宝贵工具。诊断分析的发展。随着各种医疗保健环境和进步对准确、高效的诊断解决方案的需求激增,该领域有望实现可观的成长。
从地区来看,亚太地区适配体产业在 2022 年录得强劲收益,预计由于对生物技术研发活动的日益关注,特别是在中国、日本和印度,该产业将显着成长。慢性病盛行率不断上升,加上人口众多和老化,刺激了该地区对有效和有针对性的治疗解决方案的需求,进一步推动了适体的采用。此外,政府促进生物製药产业发展的倡议,加上学术研究机构和产业参与者之间不断加强的合作,将推动市场成长。
Aptamers Market size is estimated to grow at more than 20% CAGR from 2023 to 2032, driven by the rising prevalence of chronic diseases coupled with the surging need for targeted therapies and personalized medicine solutions. Aptamers, with their high specificity and affinity for various disease targets, are gaining traction as viable alternatives to conventional treatment modalities. Owing to their potential for precise and efficient drug delivery along with minimal off-target effects and reduced immunogenicity, aptamers are matching the growing demand for personalized medicine solutions.
Moreover, industry players are investing in R&D activities for the advancement of aptamer technology. For instance, in October 2023, Zentek Ltd. partnered with McMaster University to launch a fully owned subsidiary that would own the exclusive, international licensing rights for all aptamer-based technology.
The overall aptamers market is segmented into type, application, technology, end-use, and region.
Based on type, the RNA-based aptamers industry is set to gain significant traction from 2023-2032. With their unique ability to bind to wide range of target molecules, RNA-based aptamers have garnered significant attention in the field of therapeutics, diagnostics, and research applications. Moreover, the rising advancements in RNA aptamer selection techniques, including modified SELEX methodologies and the ongoing R&D activities to explore the potential applications of RND-based aptamers will propel the segment growth. For instance, in September 2023, the FDA authorized Iveric Bio/Astellas' avacincaptad pegol for geographic atrophy secondary to treat age-associated macular degeneration.
In terms of application, the aptamers market size from the diagnostics segment is expected to record robust growth through 2032. Owing to their rapid and sensitive detection capabilities along with higher potential for multiplexing and cost-effective production, aptamers have emerged as valuable tools in the development of diagnostic assays. With the upsurge in demand for accurate and efficient diagnostic solutions across various healthcare settings and advancements, the segment is poised to record considerable growth.
Regionally, the Asia Pacific aptamers industry recorded robust proceeds in 2022 and is expected to foresee significant growth fueled by the increasing focus on biotechnological R&D activities, particularly in China, Japan, and India. The rising prevalence of chronic diseases coupled with the presence of large and aging population is bolstering the demand for effective and targeted therapeutic solutions in the region, further driving the adoption of aptamers. Additionally, government initiatives for promoting the development of the biopharmaceutical sector coupled with increasing collaboration between academic research institutions and industry players will propel the market growth.